Sialorrhea in Patients with Parkinson's Disease: Safety and Administration of Botulinum Neurotoxin

被引:21
|
作者
Egevad, Gustav [1 ]
Petkova, Valentina Yankova [1 ]
Vilholm, Ole Jakob [1 ]
机构
[1] Lillebaelt Hosp, Dept Neurol, Vejle, Denmark
关键词
Parkinson's disease; sialorrhea; drooling; botulinum neurotoxin; treatment; AMYOTROPHIC-LATERAL-SCLEROSIS; TOXIN TYPE-A; DOUBLE-BLIND; INJECTIONS; EFFICACY; SALIVA; TRIAL;
D O I
10.3233/JPD-140379
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Sialorrhea may present as a troublesome symptom in patients suffering from Parkinson's disease. Current options for treatment include anticholinergic drugs, irradiation, surgery, oral-motor and behavioural therapies, and injection of botulinum neurotoxin (BoNT) in the salivary glands. The aim of this study is to evaluate the safety and administration of BoNT as a treatment for sialorrhea in patients with Parkinson's disease (PD) based on a review of the studies conducted so far in this field. A PubMed search was conducted using the major keywords sialorrhea, botulinum neurotoxin, botulinum toxin and Parkinson's disease. The literature search identified 12 articles, which were selected for further analysis. Few adverse effects were described in the studies included in this present review. Various treatment strategies, including different medication dosages, were applied in the studies. BoNT treatment is safe for sialorrhea in patients with PD. Positive effect is well documented, and there have been relatively few reported adverse effects, which have been mild and transient. Based on this review, a treatment algorithm is proposed. Ultrasound guidance may not be necessary when injecting the parotid gland but may improve the effect and safety of administration, especially when injecting the submandibular glands.
引用
下载
收藏
页码:321 / 326
页数:6
相关论文
共 50 条
  • [31] Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease
    Nicaretta, Denise Hack
    Zuma de Rosso, Ana Lucia
    Maliska, Carmelindo
    Barbosa Costa, Milton Melclades
    PARKINSONISM & RELATED DISORDERS, 2008, 14 (04) : 338 - 341
  • [32] Dysphagia and sialorrhea associated with Parkinson's disease
    Nicaretta, D. H.
    Rosso, A. L. Z.
    de Mattos, J. P.
    Maliska, C.
    Nascimento, O. J. M.
    Novis, S. A. P.
    de Freitas, M. R.
    Moraes, M. A.
    Miliauskas, C. R.
    Campos, F. S.
    Bastos, L. T.
    Costa, M. M. B.
    MOVEMENT DISORDERS, 2010, 25 (07) : S333 - S333
  • [33] Glycopyrroniumbromide for the treatment of sialorrhea in Parkinson's disease
    Arbouw, M. E. L.
    Movig, K. L. L.
    Koopmann, M.
    Poels, P. J. E.
    Guchelaar, H. -J.
    Egberts, T. C. G.
    Neef, C.
    van Vugt, J. P. P.
    MOVEMENT DISORDERS, 2009, 24 : S255 - S255
  • [34] NH004: A treatment for Sialorrhea in Parkinson's disease patients
    Gamzu, E. R.
    Katzman, D.
    Farber, N. M.
    MOVEMENT DISORDERS, 2008, 23 (11) : 1630 - 1630
  • [35] Glycopyrroniumbromide for the treatment of sialorrhea in parkinson's disease
    Arbouw, Maurits E. L.
    Movig, Kris L. L.
    Koopmann, Miriam
    Poels, Petra J. E.
    Guchelaar, Henk-Jan
    Egberts, Toine C. G.
    Neef, Cees
    van Vugt, Jeroen P. P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 782 - 782
  • [36] Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease
    Lloret, Santiago Perez
    Arce, Gabriel Piran
    Rossi, Malco
    Nemet, Maria Laura Caivano
    Salsamendi, Paz
    Merello, Marcelo
    MOVEMENT DISORDERS, 2007, 22 (01) : 107 - 111
  • [37] Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review
    Mitchell, Steven D.
    Sidiropoulos, Christos
    TOXINS, 2021, 13 (03)
  • [38] Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson's Disease Model
    Itakura, Masanori
    Kohda, Tomoko
    Kubo, Takeya
    Semi, Yuko
    Nishiyama, Kazuhiro
    Azuma, Yasu-Taka
    Nakajima, Hidemitsu
    Kozaki, Shunji
    Takeuchi, Tadayoshi
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2014, 76 (08): : 1189 - 1193
  • [39] Early Use of Botulinum Neurotoxin Treatment for Clozapine-Induced Sialorrhea
    Moss, Lori
    JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY, 2021, 62 (06): : 663 - 664
  • [40] Does Botulinum neurotoxin type A treatment for sialorrhea change oral health?
    Janne Tiigimäe-Saar
    Pille Taba
    Tiia Tamme
    Clinical Oral Investigations, 2017, 21 : 795 - 800